Piroxicam is a commonly used non-steroidal anti-inflammatory drug. Its advantages include its high efficacy, its long plasma half life (mean of 38 hours), which enables it to be taken as a single daily dose, and its supposedly low incidence of gastrointestinal side effects. We report, however, on four patients with peptic ulcers induced by piroxicam seen over four months. None had had dyspeptic symptoms previously, and none was taking other ulcerogenic drugs. In conclusion, we suspect that piroxicam may cause considerable peptic ulceration. The only way to test this hypothesis would be for patients to undergo endoscopy before and some weeks after a course of this drug.
Since this paper was accepted we have admitted a fifth patient with ulcers induced by piroxicam. 
Long term suppression of prolactin concentrations after bromocriptine induced regression of pituitary prolactinomas
Elsewhere we reported our experience of bromocriptine treatment for hyperprolactinaemia in a series of 36 women, 29 of whom showed radiological abnormalities of the pituitary fossa.5 Twenty of the original patients, who had abnormal fossas on initial assessment, remained under follow up surveillance for a further four years. Of these, three were unable to tolerate bromocriptine and received no definitive treatment, five are still receiving bromocriptine, and one discontinued treatment after two successful pregnancies. The remaining 11 patients treated with bromocriptine showed evidence of tumour regression on serial radiological investigation and treatment was stopped. We describe the subsequent progress of these 11 patients.
Present series
Radiological assessment of pituitary fossa-Initial assessment was by thin section pituitary tomography supplemented where indicated by computed tomography (CT). When necessary metrizamide cisternography was performed. Subsequent radiological assessment was carried out at intervals of 12-18 months using a combination of thin section tomography and CT.
Treatment regimen-The dose of bromocriptine was titrated against plasma prolactin concentrations until the value had fallen into the normal range (<500 mU/l). Prolactin assays were performed every three to six months once the appropriate daily dose of bromocriptine had been determined. In general bromocriptine was discontinued when pregnancy had been confirmed -that is, three weeks after ovulation-and resumed after delivery. In two patients who showed evidence of suprasellar extension bromocriptine was continued throughout pregnancy in one instance and from 32 weeks of gestation to delivery in another. Visual field assessment was carried out at three to six month intervals. Once radiological evidence of regression of the prolactinoma had been obtained bromocriptine was stopped. Prolactin concentrations were monitored initially at monthly intervals and subsequently every three to six months. Radiological reassessment was undertaken at intervals of one year.
Patients and outcome-The 11 patients were aged 19-33 years. Pretreatment prolactin concentrations ranged between 2000 and 6400 mU/l. The daily dose of bromocriptine required to secure normoprolactinaemia lay between 2-5 and 10-0 mg. Seven women achieved at least one viable pregnancy during treatment. The duration of treatment required to secure regression in patients who achieved pregnancy (mean 28-7 months; range 19-40 months) was generally less than in the group who did not become pregnant (mean 67-0 months; range 42-88 months). One patient proved to have pituitary gonadotrophin failure and required treatment with exogenous gonadotrophins to achieve her pregnancy. She remained amenorrhoeic after delivery. With the exception of one woman in whom the recurrence of symptoms necessitated resumption of bromocriptine after three months, the remainder continued to ovulate regularly as documented by progesterone assays; plasma prolactin concentrations, although not necessarily within the normal range, remained suppressed ( figure) . No re-expansion of the prolactinomas was detected radiologically.
Comment
Bergh and his colleagues reported the recurrence of amenorrhoea and anovulation in 30 of 37 women within five months of stopping long term bromocriptine treatment.2 Seven continued to have ovulatory menstruation, though hyperprolactinaemia recurred in all within one year of stopping treatment. Only two had shown radiological evidence of regression of their prolactinomas. A recent report on 15 cases recorded that after regression of pituitary prolactinomas induced by dopamine agonists withdrawal of treatment was generally followed by recurrence of hyperprolactinaemia and associated symptoms without radiological evidence of re-expansion of the tumour. 3 Follow up of 24 patients who underwent successful transphenoidal selective adenectomy for microprolactinomas showed a 50",, recurrence rate within six years of surgery. 4 The recurrence of microprolactinomas after surgical removal together with the persistence of prolactin concentrations above normal after bromocriptine induced regression suggests that such subjects may have an underlying hypothalamic defect in the dopaminergic control of pituitary lactotrophs which predisposes to the development of prolactinomas. If this should prove to be the case medical treatment with a dopamine agonist would appear to be the logical approach to the problem.
In our study there were indications that pregnancy may exercise a synergistic effect with bromocriptine to induce regression of prolactinomas. The findings are in keeping with those of the Munich group, who observed a fall in prolactin concentrations during bromocriptine induced pregnancy in seven women and that normoprolactinaemia persisted in five after delivery.
